inolimomab
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04289103)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-2 receptor alpha chainANTAGONIST
IL2RA antagonist
- Interleukin-2 receptor alpha chainINHIBITOR
IL2RA inhibitor
- Peripheral myelin protein 22INHIBITOR
PMP22 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108370 ↗
Also known as
- bt563
- bt 563
- bt-563
- bt-563
- inolimomab
- inolimomab
- leucotac
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04289103 | Phase 3 | Oct 31, 2020 | ElsaLys Biotech |
| NCT05047328 | N/A | — | ElsaLys Biotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ElsaLys Biotech | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1